Table 2 Interview guide (adapted to each partner country)

• What are the key changes, policies, innovations in SMS and diabetes type 2 over the last 10 years? Why have these been the most important ones? What changes have these led to?

• Why do you think policy has changed in the way that it has?

• Who are the most important stakeholders in this area? How have they influenced the agenda around SMS?

• What is the role of drug companies nationally internationally? Do you have a view of current policy around the role of drug companies or how they influence the agenda in this area?

• What is the involvement of private companies in SMS (e.g. through lifestyle programmes and subcontracting of health related local services)?

• How is the broader healthcare system organised to support long term condition management?

• What is the role of health prevention and policy in SMS?

• What are government attitudes to lifestyle and behavioural changes at the level of patients?

• What are the funding and incentives structures in the health system, particularly at the level of public health and primary care?

• What programmes and policies are there for the prevention of long term conditions , guidelines for monitoring, prescribing, and care for diabetes type 2?

• What are the public attitudes to SMS and diabetes type 2?

• What have been the main media constructions of the epidemic of diabetes type 2 and who is at risk?

• How has policy around and towards inequalities had an impact?

• What if any is the impact of the fiscal crises?